Login to Your Account

Clinic Roundup

Friday, July 13, 2012

• OncoMed Pharmaceuticals Inc., of Redwood City, Calif., said patient dosing has begun in a Phase I trial of OMP-54F28, a fusion protein based on a truncated form of the Frizzled8 receptor, in advanced solid tumor cancers. The open-label, dose-escalation study will assess safety, immunogenicity, pharmacokinetics, biomarkers and initial signals of efficacy. The drug is part of the firm's collaboration with Leverkusen, Germany-based Bayer AG.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription